An evidence based therapeutic approach to hereditary and acquired angioedema

Current Opinion in Allergy and Clinical Immunology

Volumn 14, Issue 4, 2014, Pages 354-362

  Bork, Konrad ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

acquired angioedema; acute treatment; c1 inhibitor; c1 INH deficiency; hereditary angioedema; prophylaxis

Indexed keywords

ANDROGEN; ANTIFIBRINOLYTIC AGENT; BRADYKININ B2 RECEPTOR ANTAGONIST; COMPLEMENT COMPONENT C1S INHIBITOR; ECALLANTIDE; ICATIBANT; KALLIKREIN INHIBITOR; PLASMA KALLIKREIN; KALLIKREIN;

ACQUIRED ANGIOEDEMA; ANGIONEUROTIC EDEMA; COST OF ILLNESS; DRUG SELF ADMINISTRATION; EVIDENCE BASED PRACTICE; HUMAN; MORBIDITY; MORTALITY; PATHOGENESIS; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; ANGIOEDEMAS, HEREDITARY; ANTAGONISTS AND INHIBITORS; EVIDENCE BASED MEDICINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS;

ANGIOEDEMAS, HEREDITARY; BRADYKININ B2 RECEPTOR ANTAGONISTS; COMPLEMENT C1 INHIBITOR PROTEIN; EVIDENCE-BASED MEDICINE; HUMANS; KALLIKREINS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84903733959     PISSN: 15284050     EISSN: 14736322     Source Type: Journal    
DOI: 10.1097/ACI.0000000000000082     Document Type: Review

References (51)

1. Bork K, Hardt J, Witzke G. Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency. J Allergy Clin Immunol 2012; 130:692-697.
2. Cicardi M, Bork K, Caballero T, et al. Evidence-based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group. Allergy 2012; 67:147-157.
3. Craig T, Aygoren-Pursun E, Bork K, et al. WAO guideline for the management of hereditary angioedema. World Allergy Organ J 2012; 5:182-199.
4. Bork K, Maurer M, Bas M, et al. German guidelines for hereditary angioedema due to C1-INH deficiency. Mainz, Germany: German Society for Angioedema Research; 2011. Available in English at www.angioedema.de/englisch/ infos. htm. [Accessed March 2014]
5. Gandhi PK, Gentry WM, Bottorff MB. Thrombotic events associated with C1 esterase inhibitor products in patients with hereditary angioedema: investigation from the United States Food and Drug Administration adverse event reporting system database. Pharmacotherapy 2012; 32:902-909.
6. Bork K, Bygum A, Hardt J. Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients. Ann Allergy Asthma Immunol 2008; 100:153-161.
7. Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol 2009; 124:801-808.
8. Bork K, Meng G, Staubach P, Hardt J. Treatment with C1 inhibitor concentrate in abdominal pain attacks of patients with hereditary angioedema. Transfusion 2005; 45:1774-1784.
9. Farkas H, Jakab L, Temesszentandrási G, et al. Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy. J Allergy Clin Immunol 2007; 120:941-947.
10. Bork K, Staubach P, Hardt J. Treatment of skin swellings with C1-inhibitor concentrate in patients with hereditary angio-oedema. Allergy 2008; 63:751-757.
11. Rizk C, Karsh J, Santucci S, Yang W. Self-administration of intravenous C1 esterase inhibitor in hereditary angioedema. CMAJ 2013; 185:791-792.
12. Bork K. Pasteurized and nanofiltered, plasma-derived C1 esterase inhibitor concentrate for the treatment of hereditary angioedema. Immunotherapy 2014. [Epub ahead of print]
13. Bork K, Hardt J. Hereditary angioedema: increased number of attacks after frequent treatments with C1 inhibitor concentrate. Am J Med 2009; 122:780-783.
14. Kalfus I, Frank M. C1 inhibitor therapy and hereditary angioedema. Am J Med 2010; 123:e15-e17.
15. Bork K, Hardt J. Hereditary angioedema: long-term treatment with one or more injections of C1 inhibitor concentrate per week. Int Arch Allergy Immunol 2011; 154:81-88.
16. Cinryze: European Public Assessment Report. London, UK: European Medicines Authority; 2011. Available at http://www.ema.europa.eu/ema/index.jsp? curl=pages/medicines/human/medicines/001207/human-med-001448. jsp&mid=WC0b01ac058001d124. [Accessed March 2014]
17. Lumry W, Manning ME, Hurewitz DS, et al. Nanofiltered C1-esterase inhibitor for the acute management and prevention of hereditary angioedema attacks due to C1-inhibitor deficiency in children. J Pediatr 2013; 162:1017-1022; 1022.e1-1022.e2.
18. Tourangeau LM, Castaldo AJ, Davis DK, et al. Safety and efficacy of physiciansupervised self-managed c1 inhibitor replacement therapy. Int Arch Allergy Immunol 2012; 157:417-424.
19. Hock FJ, Wirth K, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vitro studies. Br J Pharmacol 1991; 102:769-773.
20. Wirth KF, Hock J, Albus U, et al. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol 1991; 102:774-777.
21. Bork K, Yasothan U, Kirkpatrick P. Icatibant. Nat Rev Drug Discov 2008; 7:801-802.
22. Bork K, Frank J, Grundt B, et al. Treatment of acute edema attacks in hereditary angioedema with a bradykinin receptor-2 antagonist (Icatibant). J Allergy Clin Immunol 2007; 119:1497-1503.
23. Cicardi M, Banerji A, Bracho F, et al. Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema. N Engl J Med 2010; 363:532-541.
24. Lumry WR, Li HH, Levy RJ, et al. Randomized placebo-controlled trial of the bradykinin B receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial. Ann Allergy Asthma Immunol 2011; 107:529-537.
25. Maurer M, Aberer W, Bouillet L, et al. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment. PLoS One 2013; 8:e53773.
26. Aberer W, Maurer M, Reshef A, et al. Open-label, multicenter study of selfadministered icatibant for attacks of hereditary angioedema. Allergy 2014; 69:305-314.
27. Cicardi M, Levy RJ, McNeil DL, et al. Ecallantide for the treatment of acute attacks in hereditary angioedema. N Engl J Med 2010; 363:523-531.
28. Levy RJ, Lumry WR, McNeil DL, et al. EDEMA4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema. Ann Allergy Asthma Immunol 2010; 104:523-529.
29. Sheffer AL, MacGinnitie AJ, Campion M, et al. Outcomes after ecallantide treatment of laryngeal hereditary angioedema attacks. Ann Allergy Asthma Immunol 2013; 110:184.e2-188.e2.
30. MacGinnitie AJ, Davis-Lorton M, Stolz LE, Tachdjian R. Use of ecallantide in pediatric hereditary angioedema. Pediatrics 2013; 132:e490-e497.
31. Li HH, Campion M, Craig TJ, et al. Analysis of hereditary angioedema attacks requiring a second dose of ecallantide. Ann Allergy Asthma Immunol 2013; 110:168-172.
32. Zuraw B, Cicardi M, Levy RJ, et al. Recombinant human C1-inhibitor for the treatment of acute angioedema attacks in patients with hereditary angioedema. J Allergy Clin Immunol 2010; 126:821.e14-827.e14.
33. Riedl MA, Levy RJ, Suez D, et al. Efficacy and safety of recombinant C1 inhibitor for the treatment of hereditary angioedema attacks: a North American open-label study. Ann Allergy Asthma Immunol 2013; 110:295-299.
34. Riedl MA, Bernstein JA, Li H, et al. Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial. Ann Allergy Asthma Immunol 2014; 112:163.e1-169.e1.
35. Sheffer AL, Austen KF, Rosen FS. Tranexamic acid therapy in hereditary angioneurotic edema. N Engl J Med 1972; 287:452-454.
36. Fust G, Farkas H, Csuka D, et al. Long-term efficacy of danazol treatment in hereditary angioedema. Eur J Clin Invest 2011; 41:256-262.
37. Zuraw BL, Busse PJ, White M, et al. Nanofiltered C1 inhibitor concentrate for treatment of hereditary angioedema. N Engl J Med 2010; 363:513-522.
38. Zuraw BL, Kalfus I. Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema. Am J Med 2012; 125:938.e1-938.e7.
39. Bernstein JA, Manning ME, Li H, et al. Escalating doses of C1 esterase inhibitor (CINRYZE) for prophylaxis in patients with hereditary angioedema. J Allergy Clin Immunol Pract 2014; 2:77.e1-84.e1.
40. Bork K, Witzke G. Long-term prophylaxis with C1-inhibitor (C1 INH) concentrate in patients with recurrent angioedema caused by hereditary and acquired C1-inhibitor deficiency. J Allergy Clin Immunol 1989; 83:677-682.
41. Martinez-Saguer I, Heller C, Fischer D, et al. Prophylactic treatment with pasteurised C1 inhibitor in hereditary angioedema (HAE): a prospective 32 months follow up. Blood 1999; 94 (Suppl. 1); abstract #1032: 2339.
42. Tallroth GA. Long-term prophylaxis of hereditary angioedema with a pasteurized C1 inhibitor concentrate. Int Arch Allergy Immunol 2011; 154:356-359.
43. Reshef A, Moldovan D, Obtulowicz K, et al. Recombinant human C1 inhibitor for the prophylaxis of hereditary angioedema attacks: a pilot study. Allergy 2013; 68:118-124.
44. Bork K, Barnstedt SE, Koch P, Traupe H. Hereditary angioedema with normal C1-inhibitor activity in women. Lancet 2000; 356:213-217.
45. Dewald G, Bork K. Missense mutations in the coagulation factor XII (Hageman factor) gene in hereditary angioedema with normal C1 inhibitor. Biochem Biophys Res Commun 2006; 343:1286-1289.
46. Bork K, Wulff K, Meinke P, et al. A novel mutation in the coagulation factor 12 gene in subjects with hereditary angioedema and normal C1-inhibitor. Clin Immunol 2011; 141:31-35.
47. Kiss N, Barabas E, Várnai K, et al. Novel duplication in the F12 gene in a patient with recurrent angioedema. Clin Immunol 2013; 149:142-145.
48. Bork K. Hereditary angioedema with normal C1 inhibitor. Immunol Allergy Clin North Am 2013; 33:457-470.
49. Zanichelli A, Bova M, Coerezza A, et al. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study. Allergy 2012; 67:1074-1077.
50. Bygum A, Vestergaard H. Acquired angioedema - occurrence, clinical features and associated disorders in a Danish nationwide patient cohort. Int Arch Allergy Immunol 2013; 162:149-155.
51. Patel NS, Fung SM, Zanichelli A, et al. Ecallantide for treatment of acute attacks of acquired C1 esterase inhibitor deficiency. Allergy Asthma Proc 2013; 34:72-77.